Literature DB >> 30145835

Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP.

Jian Gao1, Yingxue Rong1, Yuxing Huang1, Peng Shi1, Xitao Wang2, Xuan Meng3,4, Jiahong Dong5, Congying Wu1.   

Abstract

A majority of hepatocellular carcinomas (HCCs) combine with liver cirrhosis. The cirrhotic liver has been implicated in interfering with the effects of HCC-targeted drugs, including sorafenib. Alterations in the tumor microenvironment of the cirrhotic liver include both biochemical and biomechanical factors. In this study, we induced sorafenib resistance in HCC cells. We observed changes in cell morphology, cytoskeletal architecture, and cellular stiffness in these sorafenib-resistant cells, resembling those adapted to stiffer substrates. To examine the contribution of mechanical factors in HCC cell growth and drug resistance, we used an in vitro cell culture system with adjustable stiffness mimicking the normal or cirrhotic liver tissues. We identified that mechanical adaptation conferred HCC cells with increased motility and sorafenib resistance. We further reported the mechanism underlying the involvement of the transcription coactivator YAP. Our results underline the important role of mechanical factors in the interaction between tumor cells and their microenvironment.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  YAP; drug resistance; hepatocellular carcinoma (HCC); sorafenib; tumor biomechanics; tumor cell migration

Year:  2018        PMID: 30145835     DOI: 10.1002/jcp.27078

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Mechanotransduction in Liver Diseases.

Authors:  Ningling Kang
Journal:  Semin Liver Dis       Date:  2019-11-04       Impact factor: 6.115

Review 2.  Matrix Stiffness Contributes to Cancer Progression by Regulating Transcription Factors.

Authors:  Seiichiro Ishihara; Hisashi Haga
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

Review 3.  Hippo signalling in the liver: role in development, regeneration and disease.

Authors:  Jacquelyn O Russell; Fernando D Camargo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-21       Impact factor: 73.082

4.  Reactive oxygen species-induced activation of Yes-associated protein-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma.

Authors:  Yuri Cho; Min Ji Park; Koeun Kim; Sun Woong Kim; Wonjin Kim; Sooyeon Oh; Joo Ho Lee
Journal:  World J Gastroenterol       Date:  2020-11-14       Impact factor: 5.742

5.  Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes-Associated Protein 1 Activation and Transient Expansion of Stem-Like Cancer Cells.

Authors:  Darko Castven; Carolin Czauderna; Diana Becker; Sharon Pereira; Jennifer Schmitt; Arndt Weinmann; Viral Shah; Jovana Hajduk; Friederike Keggenhoff; Harald Binder; Tobias Keck; Stefanie Heilmann-Heimbach; Marcus A Wörns; Snorri S Thorgeirsson; Kai Breuhahn; Peter R Galle; Jens U Marquardt
Journal:  Hepatol Commun       Date:  2021-11-24

Review 6.  Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights.

Authors:  Xinchen Tian; Tinghao Yan; Fen Liu; Qingbin Liu; Jing Zhao; Huabao Xiong; Shulong Jiang
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

7.  Mechano-signalling, induced by fullerene C60 nanofilms, arrests the cell cycle in the G2/M phase and decreases proliferation of liver cancer cells.

Authors:  Malwina Sosnowska; Marta Kutwin; Sławomir Jaworski; Barbara Strojny; Mateusz Wierzbicki; Jarosław Szczepaniak; Maciej Łojkowski; Wojciech Święszkowski; Jaśmina Bałaban; André Chwalibog; Ewa Sawosz
Journal:  Int J Nanomedicine       Date:  2019-08-06

8.  CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma.

Authors:  Shigeki Suemura; Takahiro Kodama; Yuta Myojin; Ryoko Yamada; Minoru Shigekawa; Hayato Hikita; Ryotaro Sakamori; Tomohide Tatsumi; Tetsuo Takehara
Journal:  Cancers (Basel)       Date:  2019-09-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.